Skip to content
OpenCapital
Get started

Kiniksa Pharmaceuticals International, plc KNSA PP&E (Net)

PP&E (Net) at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
$3.44M-4.9%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$41.62M-15.4%
Apogee Therapeutics, Inc. logo
Apogee Therapeutics, Inc.APGE
$5.28M-7.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$4.94M-26.2%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$142.4M+38.4%
LQD
Liquidia CorporationLQDA
$20.84M+146%

Segments

By segment

See full
Pharmaceutical$1.99M—

By geography

See full
Outside United States And United Kingdom$259K—

Other financials

Income statement

See full
Revenue$214.3M+55.5%
Gross profit$193.5M+61.3%
Operating income$29.3M+121%
Net income$22.6M+165%
EPS (diluted)$0.27+145%

Balance sheet

See full
Cash & equivalents$190.0M+20.9%
Total debt$9.0M-9.0%
Total equity$605.7M+32.4%
Total assets$825.3M+37.7%

Cash flow

See full
Operating cash flow$50.2M+125%
CapEx$161.0K+62.6%
Free cash flow$50.0M+125%

Valuation

See full
Market cap$4.58B+128%

Profitability

See full
Gross margin89.3%+3.5pp
Operating margin12.4%+10.2pp
Net margin9.7%+7.6pp
FCF margin21.8%+12.2pp

Returns & leverage

See full
Return on equity13.7%+11.3pp
Debt / equity0×0.0×
Current ratio3.8×+0.1×

Where this comes from

Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Kiniksa Pharmaceuticals International, plc's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Kiniksa Pharmaceuticals International, plc's PP&E (net)?
Kiniksa Pharmaceuticals International, plc (KNSA) reported PP&E (net) of $1.99M in Q1 2026.
How has Kiniksa Pharmaceuticals International, plc's PP&E (net) changed year-over-year?
Kiniksa Pharmaceuticals International, plc's PP&E (net) increased by 227.7% year-over-year, from $606K to $1.99M.
What is the long-term trend for Kiniksa Pharmaceuticals International, plc's PP&E (net)?
Over 5 years (2020 to 2025), Kiniksa Pharmaceuticals International, plc's PP&E (net) has grown at a -13.7% compound annual growth rate (CAGR), from $4.05M to $1.94M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.